Davita Inc vs Funko Inc — how do they compare? Davita Inc trades at $179.56 (market cap $11.29B), while Funko Inc trades at $6.55 (market cap $363.97M). The key difference: Davita Inc is far larger — about 31× Funko Inc's market cap, and Funko Inc is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Funko Inc for 33 Days on average.
| DVA | FNKO | |
|---|---|---|
Market Cap | $11.29B | $363.97M |
Volume | 582,204 | 1,422,651 |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $7.10 |
52-Week Low | $103.87 | $2.81 |
Typical Hold Time | 113 Days | 33 Days |
Enterprise Value | $24.01B | $584.62M |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, with a bearish technical signal and neutral oscillators. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $4.02 beating expectations of $3.88. Revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026, though net margins have fluctuated. Recent partnership expansion with Humana for value-based kidney care represents significant business development.
DVA presents a mixed outlook with 43% analyst buy ratings and a $235.67 price target suggesting 33% upside. However, high debt levels (65.55% debt-to-asset ratio) and regulatory risks in healthcare weigh on fundamentals. The stock's current valuation at P/E 15 and P/S 0.88 appears reasonable relative to earnings growth potential, making it attractive for value investors despite near-term bearish technicals.
Funko (FNKO) trades at $6.31, up 3.27% with strong technical momentum and bullish moving average signals. The company shows improving fundamentals with recent earnings beats and raised 2026 EBITDA guidance to $105M. Revenue declined to $908M in 2025 but shows stabilization with 2026 projections at $933M. Analyst consensus is mixed with 42.9% buy ratings and $7.58 price target, representing 20% upside potential.
Investment opportunity centers on turnaround execution with improving margins and debt reduction. Key risks include negative net income margins, competitive pressures in collectibles, and sensitivity to consumer discretionary spending. The stock offers value with low P/S of 0.38x but requires sustained profitability improvement to justify higher valuations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →